Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599350 | 0.91 | LMNA (0.45) | LMNAKMT2AALDH1A1HTTADRB2 | |
| Hydrochloric Acid SCHEMBL3529730 | 0.90 | LMNA (0.44) | LMNAKMT2AALDH1A1HTTADRB2 | |
| SCHEMBL11250163 | 0.85 | KMT2A (0.43) | LMNAKMT2ASRCALDH1A1CYP3A4 | |
| SCHEMBL28064960 | 0.84 | SRC (0.57) | LMNAKMT2ASRCALDH1A1MAPT | |
| SCHEMBL3335866 | 0.84 | SRC (0.57) | LMNAKMT2ASRCALDH1A1MAPT | |
| SCHEMBL5983603 | 0.84 | SRC (0.57) | LMNAKMT2ASRCALDH1A1MAPT | |
| SCHEMBL7457601 | 0.83 | SLC7A5 (0.40) | LMNAKMT2ASRCADRB3KDM4E | |
| SCHEMBL7347467 | 0.81 | CPN1 (0.47) | LMNAKMT2ASRCALDH1A1ADRB2 | |
| SCHEMBL7461910 | 0.81 | CPN1 (0.47) | LMNAKMT2ASRCALDH1A1ADRB2 | |
| SCHEMBL9300518 | 0.81 | ALDH1A1 (0.47) | LMNAKMT2ASRCALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598849-A | Compound for degrading TMPRSS2 protein in targeted ubiquitination, preparation method and application thereof | 浙江工业大学 | 2024-09-06 | — | — | CN | claimed |
| CN-118344265-A | Amide compound and preparation method and application thereof | 河北大学 | 2024-07-16 | — | — | CN | claimed |
| CN-119613701-A | Method for synthesizing functionalized polyether in multi-proton system | 华南理工大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-118598849-A | Compound for degrading TMPRSS2 protein in targeted ubiquitination, preparation method and application thereof | 浙江工业大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-118344265-A | Amide compound and preparation method and application thereof | 河北大学 | 2024-07-16 | — | — | CN | disclosed |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| CN-114213435-B | Preparation and application of bis- (10-deoxydihydroartemisinin) -phloroglucinol derivative | 云白药征武科技(上海)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220106278-A1 | REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS | UNIVERSITY OF DELAWARE (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114213435-A | Preparation and application of bis- (10-deoxydihydroartemisinin) -phloroglucinol derivative | 云白药征武科技(上海)有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-1778652-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | EntreMed, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | ENTREMED, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006023844-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | ENTREMED, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-5545627-A | VASODILATORS, DIURETICS, IMMUNOSUPPRESSANTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5449662-A | Atrial natriuretic peptide clearance inhibitors which resist degradation | SCIOS NOVA INC. (US) | 1995-09-12 | — | — | US | disclosed |
| US-5298508-A | Compounds as ligands for cardiovascular disorders or stimulant of immunology | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0429537-A4 | ATRIAL NATRIURETIC PEPTIDE CLEARANCE INHIBITORS | — | 1991-08-21 | — | — | EP | disclosed |
| EP-0429537-A1 | ATRIAL NATRIURETIC PEPTIDE CLEARANCE INHIBITORS | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990001940-A1 | ATRIAL NATRIURETIC PEPTIDE CLEARANCE INHIBITORS | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | TST, CYP4F8, CYP4Z1 | LMNA 3980/4885KMT2A 1657/4885SRC 910/4885 |
| US-20220106278-A1 | REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS | TST, CYP4F8, CYP4Z1 | LMNA 3980/4885KMT2A 1657/4885SRC 910/4885 |
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | F2RL1, PLAUR, F2R | LMNA 3260/4885KMT2A 3771/4885SRC 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.